Angel Arnaout profile picture

Contact Information

Angel Arnaout, MD MSc FRCSC FACS
613-798-5555 ext 79071

CW 1606
Ottawa Hospital General Campus
501 Smyth Road
Ottawa, ON K1H8L6

Angel Arnaout

Associate Scientist, Cancer Therapeutics Program
Ottawa Hospital Research Institute
Breast Surgical Oncologist, General Surgery
Ottawa Hospital
Assistant Professor, Department of Surgery,
University of Ottawa

Research Interests

Dr. Arnaout is part of the Ottawa Breast Cancer Biomarker Research Program, whose mandate is to develop patient centered translational breast cancer research to better the lives of women struggling through the diagnosis and treatment now. Working closely with Dr. M. Clemons (a Medical Oncologist) and Dr. C. Addison (Senior Scientist at OHRI), they have formulated the ACA team, whose approach of working together means that research findings can be rapidly translated to improve the care of women in the clinic and operating room. This research includes biomarker predictors of treatment response and future metastatic disease. She leads several "window of opportunity" clinical trials with the ultimate goal of expediting drug development in breast cancer and reducing the anxiety of patients who are waiting for definitive surgical treatment.   Dr. Arnaout’s research is also committed to improving access and delivery of high quality care to breast cancer patients in Ontario. She is the leader of two specialty programs for breast cancer patients in Ottawa that fast track patients from diagnosis to treatment. 


Brief Biography

Dr. Angel Arnaout is a Breast Surgical Oncologist at the Ottawa Hospital, Clinical Investigator at the Ottawa Hospital Research Institute, and Assistant Professor at the University of Ottawa. In addition to her clinical and scientific reserach interests, her passion as a surgeon is to aggressively treat breast cancer but with minimal side effects and cosmetic detriment, recognizing the importance of body image on the breast cancer patient. As such is also the pioneer in Oncoplastic Surgery in Ottawa; a new minimally invasive breast surgical technique that combines breast cancer surgery with plastic surgical techniques.

Selected Publications

1. Jacobs C, M Clemons, C Addison and Arnaout.A Special Considerations in the Management of Invasive Lobular Carcinoma. Accepted by Breast Journal (in press).

2. Mazzarello S, Clemons M, Jacobs C, Arnaout A, Michael F. Publishing clinical research: Ten pearls for oncology trainees and junior oncologists. Accepted by Curr Oncology (in press).  

3. Bouganim N, Spayne J, Dent R, Arnaout A, Boileau JF, Brackstone M, Clemons M. Concurrent Chemo-Radiotherapy for Locally Advanced Breast Cancer – time for a new paradigm. Accepted by Current Oncology (in press). 

4. Boileau JF, Poirier B, Basik M, Holloway C, Gaboury L, Sideris L, Meterissian S, Arnaout A, Brackstone M, McCready DR, Karp S, Wright F, Younan R, Patocskai E, Provencher L, Omeroglu A, Robidoux A. Sentinel node biopsy following neoadjuvant chemotherapy in biopsy proven node positive breast cancer: The SN FNAC study. Accepted by J Clin Oncol 2014 (in press).

5. Arnaout A, Boileau JF, Brackstone M. Surgical considerations in locally advanced breast cancer patients receiving neoadjuvant chemotherapy. Curr Opin Support Palliat Care. 2014 8(1):39-45. 

6. Hilton J, Arnaout A, Clemons M. Primary endocrine therapy as an approach for patients with localized breast cancer deemed to not to be surgical candidates. Curr Opin Support Palliat Care. 2014 8(1):53-58.

7. Simos D, Hutton B, Graham ID, Arnaout A, Caudrelier JM, Mazzarello S, Clemons M. Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer. Springerplus. 2014 Apr 5;3:176.

8. Bouganim N, Arnaout A, M Clemons. Neoadjuvant endocrine treatment for breast cancer: From bedside to bench and back again? Curr Oncol. 2014 21(1):e122-e128. Review. 

9. Arnaout A, Seely J, Smylie J, Knight K, Robertson S, Watters J. Evaluation of a Rapid Access Diagnostic Support Clinic. Ann Surg Oncol. 2013 20(10):3335-40.